Statin Therapy in Fatty Liver Disease

Key Guideline Recommendations

The American Association for the Study of Liver Diseases recommends that statins can be used to treat dyslipidemia in patients with NAFLD and NASH (Strength 1, Quality B) 1
The American Heart Association/American College of Cardiology confirms that statins are not contraindicated in patients with chronic, stable liver disease, and limited data suggest potential benefit 2
The American Diabetes Association explicitly recommends that statin therapy is safe in adults with type 2 diabetes and compensated cirrhosis from NAFLD and should be initiated or continued for cardiovascular risk reduction as clinically indicated 3
The Korean Association for the Study of the Liver recommends statins as first-line treatment to lower LDL-C and prevent atherosclerotic CVD in NAFLD patients (B1 recommendation) 4

Patients with NAFLD are at significantly increased risk for cardiovascular disease, which is their most common cause of death—not liver disease 1, 3
Cardiovascular disease is the leading cause of mortality in NAFLD patients, making aggressive cardiovascular risk factor management essential 1, 3
Statins safely lower liver enzymes and reduce cardiovascular morbidity in NAFLD patients, even with aminotransferases up to three times the upper normal limit 4
Less than 1% of patients withdrew from studies due to hepatotoxicity from statins 4

There is no evidence that patients with chronic liver disease including NAFLD are at higher risk for serious liver injury from statins than those without liver disease 1
Severe statin-associated hepatotoxicity is rare, and the incidence is not impacted by routine monitoring of transaminases 2
The only absolute contraindication to statins in liver disease is decompensated cirrhosis or acute liver failure 3, 4
Statin therapy should be used with caution and close monitoring in people with decompensated cirrhosis, given limited safety and efficacy data 3

Risk stratify for cardiovascular disease and manage cardiovascular risk factors accordingly—this is the priority, not the liver disease 1
Obtain baseline liver transaminases before starting therapy, but do not let mildly elevated enzymes deter you from prescribing statins 2
Do not routinely monitor liver enzymes during statin therapy—the FDA concluded in 2012 that routine monitoring does not prevent the rare adverse effects 2
Only measure transaminases if signs or symptoms suggesting hepatotoxicity develop (e.g., jaundice, fatigue, severe abdominal pain) 2
If asymptomatic transaminase elevation occurs (>3 times upper limit of normal), consider dose reduction or rechallenge with alternative statins—this often resolves the issue 2

If statin response is insufficient to reach LDL-C targets, add ezetimibe 4
The combination of statins and ezetimibe is safe and effective in NAFLD patients 4